Fig. 2
TransCon TLR7/8 Agonist promoted TGI, minimal systemic cytokine release, and sustained intratumoral cytokine expression. A Female BALB/c mice were SC implanted (flank) with 3 × 105 CT26 tumor cells. At a mean tumor volume of ~ 90 mm3, mice were randomized (Day 0; n = 10–15/group). The following day, animals received either TransCon Vehicle, 20 μg (eq. of resiquimod) of TransCon TLR7/8 Agonist, or 20 μg of soluble resiquimod (single IT dose, arrow). Values are represented as mean tumor volume ± SEM. On Day 14, *p < 0.005 vs all other groups, n = 6–11/group. B Female BALB/c mice were SC implanted (flank) with 3 × 105 CT26 tumor cells. At a mean tumor volume of ~ 120 mm3, mice were randomized (Day 0). The following day, animals received either TransCon Vehicle, 20 μg of TransCon TLR7/8 Agonist, or 20 μg of soluble resiquimod as a single IT dose. Plasma samples were (n = 3 independent mice/group/timepoint) assessed for cytokines by ProcartaPlex Multiplex Immunoassay. Values are represented as median plasma analyte concentration (pg/ml) with whiskers representing minimum and maximum replicate values. Points are connected for visualization purposes. *p < 0.05 Soluble Resiquimod vs TransCon Vehicle (same day), †p < 0.05 TransCon TLR7/8 Agonist vs TransCon Vehicle (same day), ‡p < 0.05 TransCon TLR7/8 Agonist vs Soluble Resiquimod (same day). C Female BALB/c mice were SC implanted (flank) with 3 × 105 CT26 tumor cells. At a mean tumor volume of ~ 115 mm3, mice were randomized (Day 0). The following day, animals received either TransCon Vehicle or 20 or 80 μg of TransCon TLR7/8 Agonist. Tumors were harvested and assessed for cytokine levels. Values are represented as the minimum, maximum, and median (black line) analyte concentrations normalized to protein input for each treatment group (n = 3/treatment/timepoint, except for the TransCon TLR7/8 Agonist treated group at the 168-h timepoint, where n = 2). *p < 0.05 vs TransCon Vehicle (same day)